China
Africa
Explore chapters and articles related to this topic
Combinatorial Polymer and Lipidoid Libraries for Nanomedicine
Published in Vladimir Torchilin, Mansoor M Amiji, Handbook of Materials for Nanomedicine, 2011
Jordan J. Green, Robert Langer, Daniel G. Anderson
Just as end-modification altered gene delivery in vitro, end-modification also altered the biodistribution of gene expression in vivo. When the lead PBAE nanoparticles are injected intraperitonealy (i.p.) using an ovarian cancer mouse model, end-modified C32-117 has greater than 100-fold higher ovarian tumor gene expression compared to unmodified C32 (Fig. 7.5(c)).60 In other work, C32-117 was also at least an order of magnitude for effective than unmodified C32 for delivery to the bladder, fat, testis, kidney, liver, and stomach.59 C32-103 similarly had over an order of magnitude more effective delivery than unmodified C32 in the prostate, bladder, fat, testis, liver, and stomach. C32-117 was most effective for bladder, kidney, and spleen delivery, whereas C32-103 was more effective for prostate delivery.59
Padé quantification of malignant and benign ovarian MRS data
Published in Dževad Belkić, Karen Belkić, Signal Processing in Magnetic Resonance Spectroscopy with Biomedical Applications, 2010
Even though there have been noteworthy results for ovarian cancer diagnosis, major problems remain that hinder broader use of in vitro MRS in this clinical area. Due to these problems, in vitro findings still cannot be considered the “gold standard” with which MRS signals encoded in vivo from the ovary could be compared. Mountford et al. [344] suggested that via the statistical classification strategy (SCS) highly accurate distinction could be made between malignant and benign tissue, based upon identification of specific spectral regions of key diagnostic importance. For ovarian cancer, 2D MRS was particularly important because of overlapping resonances, and was reported to “provide unequivocal assignment of resonances from chemical species that contribute to the various pathological states defined during (ovarian) tumor development and progression” (p. 3692). However, in his comments on the SCS used in the above-described in vitro MRS analyses, Gluch [345] questions the suitability of this methodology for more complex pathological entities, stating: “A classifier can more readily be developed when the likelihood is high of belonging to a class of either ‘yes’ or ‘no’, but when a tissue undergoes numerous stages in evolution from normal to malignant, SCS shows no superiority over conventional pathology” (p. 467). Notably, the high diagnostic accuracy was achieved by excluding the fuzzy samples.
Dendrimer as a promising nanocarrier for the delivery of doxorubicin as an anticancer therapeutics
Published in Journal of Biomaterials Science, Polymer Edition, 2021
Vanshikha Singh, Prashant Kesharwani
Furthermore, results in experiment conducted using TEM and DLS techniques suggested that these GFLG–DOX dendrimers were capable of self-aggregating into NPs much more effectively than free DOX because of their appropriate nanosize. Moreover, results derived from tumor growth curves, in vivo imaging, in vitro cytotoxicity assay, tumor growth suppression analysis, and immune histochemical assessment concluded that dendrimer–GFLG–DOX showed lower toxicity, higher aggregation, and retention at SKOV-3 ovarian tumor site suggesting these to be a potential drug carrier candidate for ovarian cancer therapy [81].